Last reviewed · How we verify

NCT07179198

A Study to Evaluate the Safety and Effectiveness of Kytogen Defend in Facial Skin Quality Improvement in Adult Participants

Not yet recruiting NA Last updated 17 September 2025
What this trial tests

NA trial testing KIO021 in Skin Quality in 500 participants. Not yet recruiting.

Timeline
22 September 2025
Primary endpoint
30 June 2026
30 November 2026

Quick facts

Lead sponsorSinclair Pharmaceuticals Limited
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment500
Start date22 September 2025
Primary completion30 June 2026
Estimated completion30 November 2026

Drugs / interventions tested

Conditions studied

Sponsor

Sinclair Pharmaceuticals Limited

Who can join

18 and older, any sex, with Skin Quality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was designed to evaluate the efficacy and safety of KIO021, an injectable solution for carboxymethyl chitosan, for temporary improvement of facial skin condition. Designed for forward-looking effectiveness. To achieve this, it is planned that 500 subjects with dry skin and dull complexion on the face will be included in the injection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sinclair Pharmaceuticals Limited trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07179198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing